MX2021014195A - Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer. - Google Patents
Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer.Info
- Publication number
- MX2021014195A MX2021014195A MX2021014195A MX2021014195A MX2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A
- Authority
- MX
- Mexico
- Prior art keywords
- naphthoquinone
- cancer
- complexes
- treatment
- functionalized gold
- Prior art date
Links
- ZRKYGJAXMUMYJX-UHFFFAOYSA-N C=C1C(C2=CC=CC=C2C(C1)=O)=O.[Au] Chemical class C=C1C(C2=CC=CC=C2C(C1)=O)=O.[Au] ZRKYGJAXMUMYJX-UHFFFAOYSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/10—Silver compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción se refiere a compuestos de naftoquinona de carbeno de oro funcionalizados y sales de los mismos. En algunos aspectos, estos compuestos pueden utilizarse para tratar el cáncer, incluidos los cánceres que son resistentes a uno o más de otros agentes quimioterapéuticos tales como cisplatino o agentes quimioterapéuticos de platino. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden los compuestos de naftoquinona de carbeno de oro. La presente descripción también proporciona métodos para preparar una vacuna contra el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851187P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/034415 WO2020237225A1 (en) | 2019-05-22 | 2020-05-22 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014195A true MX2021014195A (es) | 2022-02-21 |
Family
ID=73459479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014195A MX2021014195A (es) | 2019-05-22 | 2020-05-22 | Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220340601A1 (es) |
| EP (1) | EP3972981A4 (es) |
| JP (1) | JP2022532801A (es) |
| KR (1) | KR20220024123A (es) |
| CN (1) | CN114174305A (es) |
| AU (1) | AU2020279478A1 (es) |
| CA (1) | CA3140716A1 (es) |
| IL (1) | IL288176A (es) |
| MX (1) | MX2021014195A (es) |
| SG (1) | SG11202112856QA (es) |
| WO (1) | WO2020237225A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003483D0 (en) * | 2010-03-02 | 2010-04-14 | Univ St Andrews | Gold complexes |
| US8900654B2 (en) * | 2011-07-29 | 2014-12-02 | Thin Film Electronics, Inc. | Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds |
| JP6113194B2 (ja) * | 2012-02-13 | 2017-04-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | エンジイン化合物、その抱合体、ならびにその使用および方法 |
| US11332483B2 (en) * | 2017-06-30 | 2022-05-17 | Board Of Regents, The University Of Texas System | Naphthoquinone containing gold carbene complexes and methods of uses thereof |
-
2020
- 2020-05-22 KR KR1020217041752A patent/KR20220024123A/ko unknown
- 2020-05-22 CA CA3140716A patent/CA3140716A1/en active Pending
- 2020-05-22 AU AU2020279478A patent/AU2020279478A1/en active Pending
- 2020-05-22 EP EP20809519.0A patent/EP3972981A4/en active Pending
- 2020-05-22 WO PCT/US2020/034415 patent/WO2020237225A1/en unknown
- 2020-05-22 MX MX2021014195A patent/MX2021014195A/es unknown
- 2020-05-22 SG SG11202112856QA patent/SG11202112856QA/en unknown
- 2020-05-22 US US17/595,670 patent/US20220340601A1/en active Pending
- 2020-05-22 CN CN202080050300.4A patent/CN114174305A/zh active Pending
- 2020-05-22 JP JP2021569297A patent/JP2022532801A/ja active Pending
-
2021
- 2021-11-16 IL IL288176A patent/IL288176A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114174305A (zh) | 2022-03-11 |
| WO2020237225A1 (en) | 2020-11-26 |
| JP2022532801A (ja) | 2022-07-19 |
| US20220340601A1 (en) | 2022-10-27 |
| KR20220024123A (ko) | 2022-03-03 |
| AU2020279478A1 (en) | 2021-12-09 |
| CA3140716A1 (en) | 2020-11-26 |
| EP3972981A4 (en) | 2023-05-24 |
| EP3972981A1 (en) | 2022-03-30 |
| SG11202112856QA (en) | 2021-12-30 |
| IL288176A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| EA201890894A1 (ru) | Комбинированная терапия | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| RU2014141365A (ru) | Способ введения противоопухолевого агента | |
| EA201892797A1 (ru) | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака | |
| MX2018006953A (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer. | |
| JP2015502926A5 (es) | ||
| MX2020012611A (es) | Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes. | |
| MX2018013519A (es) | Inhibidores del potenciador del homologo zeste 2. | |
| CR20210460A (es) | Compuestos útiles en la terapia del vih | |
| MX2017016231A (es) | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
| PH12020552171A1 (en) | Bifunctional compositions for the treatment of cancer | |
| MX2023008375A (es) | Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas. | |
| EA201700286A1 (ru) | Макромолекулярные комплексы переходного металла для лечения рака и способ их получения | |
| MX2021012543A (es) | Compuestos de indoles quirales y su uso. | |
| MX2021014195A (es) | Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer. | |
| IN2014DN04596A (es) |